Failure of glucagon-like peptide-1 to induce panic attacks or anxiety in patients with panic disorder.

Journal Article (Journal Article)

The insulin secretogogue glucagon like peptide-1 (GLP-1), as well as agents which enhance GLP-1 signaling, are being studied as potential treatments for diabetes. Pre-clinical evidence suggests that these agents may have neuropsychiatric side effects; however, there have been no investigations or reports of these effects in humans. We evaluated possible anxiogenic and panicogenic properties of GLP-1 in 9 healthy subjects (age 47+/-8 years) and 7 patients with panic disorder (age 38+/-17 years) using a single-blinded intravenous GLP-1 challenge (2pmol/kg/min over 60min). We assessed the occurrence of panic attacks during and after GLP-1 infusion and the emergence of anxiety or panic symptoms using the Acute Panic Inventory (API). No patient or healthy subject experienced any panic attacks at any point during this study. Moreover, there were no significant changes in API scores following the infusion in either group. These data suggest that in humans, intraveneously administered GLP-1 does not appear to have anxiogenic or panicogenic properties, even in patients at highest risk for such reactions.

Full Text

Duke Authors

Cited Authors

  • Strawn, JR; D'Alessio, DA; Keck, PE; Seeley, RJ

Published Date

  • July 2008

Published In

Volume / Issue

  • 42 / 9

Start / End Page

  • 787 - 789

PubMed ID

  • 17888452

International Standard Serial Number (ISSN)

  • 0022-3956

Digital Object Identifier (DOI)

  • 10.1016/j.jpsychires.2007.08.007


  • eng

Conference Location

  • England